Merck's KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery - Merck
merck.comSubmitted by merckcom3067 in business
KEYTRUDA significantly improved DFS as adjuvant therapy versus observation for patients with localized MIUC and locally advanced urothelial carcinoma First positive study for KEYTRUDA as adjuvant therapy for these patients Merck (NYSE: MRK), known as MSD outs…